Phase II safety and efficacy study of panitumumab in patients with KRAS exon2 colorectal cancer refractory for cetuximab.
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 05 Dec 2016 New trial record
- 11 Oct 2016 Primary end point (Progression-free survival rate) has not been met.
- 11 Oct 2016 Results assessing efficacy and safety presented at the 41st European Society for Medical Oncology Congress.